 NEW YORK, Feb. 22, 2021 GLOBE NEWSWIRE -- Y-mAbs Therapeutics, Inc. the Company or Y-mAbs Nasdaq: YMAB, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the closing of its public offering of 2,804,878 shares of its common stock, at a public offering price of 41.00 per share, which includes the exercise in full of the underwriters option to purchase 365,853 additional shares of common stock. The aggregate gross proceeds to Y-mAbs, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, were approximately 115 million. All of the shares of common stock were offered by the Company. Y-mAbs common stock is listed on The Nasdaq Global Select Market under the ticker symbol YMAB. 